Weight Loss

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY)...

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003. Read more about the NVO stock price here....

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025). The drug targets post-bariatric hypoglycemia (PBH),...

Eli Lilly and Co. (NYSE:LLY) is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion. Expectations are slightly higher for the quarter, primarily driven by the...

Novo Nordisk A/S (NYSE:NVO) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new, higher dose of its obesity treatment, Wegovy (subcutaneous semaglutide 7.2 mg). The submission is based on clinical data from the STEP UP and STEP UP...

WW International, Inc. (WeightWatchers) (NASDAQ:WW) announced on Tuesday the successful completion of its strategic reorganization process. WeightWatchers implemented a financial reorganization transaction in May to strengthen its financial position and increase investment flexibility. The...

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy. As rival Eli Lilly and Co.’s (NYSE:LLY) Zepbound gains momentum, the Danish pharmaceutical giant is grappling with the fallout of those early...

Against a backdrop of regulatory scrutiny, with Spain investigating Novo Nordisk for alleged covert advertising of its popular weight-loss drugs, the U.K. is initiating research to determine if genetic factors impact the risk of acute pancreatitis associated with GLP-1 injections. Yellow Card...

Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on long-term treatment. While newer obesity-indicated GLP-1 therapies, such as semaglutide and tirzepatide, are...

Viking Therapeutics, Inc. (NASDAQ:VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in oral and...

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to...

Novo Nordisk A/S (NYSE:NVO) has reportedly launched its weight-loss drug Wegovy (semaglutide) in India to compete with Eli Lilly And Co. (NYSE:LLY). In March this year, U.S. pharma giant Eli Lilly launched its popular weight loss drug Mounjaro (tirzepatide) in India. It is expected to have the...

Hims & Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant. Check out the current price of HIMS...

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment. What To Know: The therapy, a long-acting, peptide-antibody conjugate administered...

On Sunday, The New England Journal of Medicine (NEJM) published results from Novo Nordisk A/S‘ (NYSE:NVO) phase 3 REDEFINE 1 trial of CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes...